2. Disease Areas
  3. Cancer Respiratory Disease
  4. Lung Cancer Respiratory Cancer
  5. Lung Adenocarcinoma

Lung Adenocarcinoma

Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC), representing approximately 40% of all lung cancer cases in the United States. It typically originates in the peripheral regions of the lungs and the bronchial lining, with tumor cells exhibiting glandular, mucinous, or solid histological patterns. Although strongly associated with a history of smoking, it is more frequently diagnosed in women and younger individuals compared to other lung cancer types. Common symptoms include fatigue, persistent cough, shortness of breath, chest or upper back pain, and hemoptysis. Staging is critical for determining treatment strategies, as management varies significantly based on disease extent. Despite declining incidence and mortality rates, lung adenocarcinoma remains the leading cause of cancer-related deaths in the U.S., underscoring its clinical significance and ongoing public health impact.

Lung Adenocarcinoma (5):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10219
    Rapamycin 53123-88-9 99.94%
    Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.
    Rapamycin
  • HY-17394
    Cisplatin 15663-27-1 99.84%
    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy.
    Cisplatin
  • HY-B0015
    Paclitaxel 33069-62-4 99.97%
    Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.
    Paclitaxel
  • HY-10999A
    Trametinib (DMSO solvate) 1187431-43-1 99.56%
    Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis. This product is in solid form, a DMSO solvate, and a stable crystalline form.
    Trametinib (DMSO solvate)
  • HY-P990651
    PY314
    PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    PY314